India, May 27 -- Palisade Bio, Inc. (PALI), a clinical-stage biopharmaceutical company, Tuesday reported positive topline data from its Phase 1 studies of PALI-2108, which is being developed for the treatment of fibrostenotic Crohns disease (FSCD) and ulcerative colitis (UC).
The Phase 1 study in adult healthy volunteers, as well as a small cohort of UC patients, met its primary endpoints of safety, tolerability, and pharmacokinetics.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
Based on these results, the company plans to start an additional safety and tolerability and PK/PD (pharmacokinetics/pharmacodynamics) exploration Phase 1b cohort in FSCD, in addition to completing long-term chronic safety ...